<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01724918</url>
  </required_header>
  <id_info>
    <org_study_id>LIVE 001</org_study_id>
    <nct_id>NCT01724918</nct_id>
  </id_info>
  <brief_title>Lacosamide IV and EEG/EKG (LIVE) Study</brief_title>
  <acronym>LIVE</acronym>
  <official_title>Lacosamide IV and EEG/EKG (LIVE) Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Lawson Health Research Institute</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>UCB Pharma GmbH</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Lawson Health Research Institute</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the effect of different intravenous doses (IV) of a
      new anti-epileptic drug (AED) called lacosamide on continuous EEG (electroencephalogram)
      rhythms (or brain rhythms) in subjects with focal seizures and the tolerability of those
      doses by patients. In addition, this study will assess the effect of IV lacosamide on EKG
      (electrocardiogram), a test which checks for problems with the electrical activity of the
      heart.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The impact of antiepileptic drugs on the EEG can vary from marked to none. A small number of
      AEDs also affect the EKG. Lacosamide is a new AED that selectively enhances slow inactivation
      of voltage-gated sodium channels, resulting in stabilization of hyperexcitable neuronal
      membranes and inhibition of repetitive neuronal firing. Information is lacking about the
      effect of lacosamide on brain and heart rhythms.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    Time limitation for recruitment exceeded. 72 of 90 estimated sample recruited.
  </why_stopped>
  <start_date>May 2013</start_date>
  <completion_date type="Actual">August 2016</completion_date>
  <primary_completion_date type="Actual">August 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in the number of interictal spikes</measure>
    <time_frame>One hour before and after drug</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in frequency and quantity of background EEG rhythms</measure>
    <time_frame>One hour before and after drug</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in EKG (QT, PR interval and heart rhythm)</measure>
    <time_frame>One hour before and after drug</time_frame>
  </secondary_outcome>
  <other_outcome>
    <measure>Adverse events</measure>
    <time_frame>Up to 4 hours after start of infusion</time_frame>
  </other_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Actual">72</enrollment>
  <condition>Focal Epilepsy</condition>
  <arm_group>
    <arm_group_label>100 mg IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>100 mg IV lacosamide infused over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>200 mg IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>200 mg IV lacosamide infused over 30 minutes</description>
  </arm_group>
  <arm_group>
    <arm_group_label>400 mg IV</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>400 mg IV lacosamide infused over 30 minutes</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lacosamide</intervention_name>
    <arm_group_label>100 mg IV</arm_group_label>
    <arm_group_label>200 mg IV</arm_group_label>
    <arm_group_label>400 mg IV</arm_group_label>
    <other_name>Vimpat</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subject is informed and given ample time and opportunity to think about her/his
             participation and has given her/his written informed consent.

          2. Adult patients 18-65 years

          3. Diagnosis of focal epilepsy

          4. Continuous EEG and video monitoring

          5. Continuous EKG

          6. Active EEG showing frequent spikes, electrographic or clinical seizures

        Exclusion Criteria:

          1. Subject has no IV access.

          2. Subject is hemodynamically unstable.

          3. Previous use of Lacosamide

          4. Primary generalized epilepsy

          5. Non-epileptic seizures

          6. No significant cardiac, renal or hepatic disease

          7. No cardiac arrhythmias including heart block

          8. Subject is a pregnant or lactating woman.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Richard McLachlan, MD, FRCPC</last_name>
    <role>Principal Investigator</role>
    <affiliation>London Health Sciences Centre, University Campus</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Foothills Medical Center</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 2T9</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>London Health Sciences Centre</name>
      <address>
        <city>London</city>
        <state>Ontario</state>
        <zip>N6A 5A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toronto Western Hospital</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5T 2S8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal University Hospital</name>
      <address>
        <city>Saskatoon</city>
        <state>Saskatchewan</state>
        <zip>S7N 0W8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>October 31, 2012</study_first_submitted>
  <study_first_submitted_qc>November 7, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 12, 2012</study_first_posted>
  <last_update_submitted>September 23, 2016</last_update_submitted>
  <last_update_submitted_qc>September 23, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 26, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Lawson Health Research Institute</investigator_affiliation>
    <investigator_full_name>Rick McLachlan</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>IV lacosamide</keyword>
  <keyword>focal epilepsy</keyword>
  <keyword>EEG</keyword>
  <keyword>EKG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Epilepsy</mesh_term>
    <mesh_term>Epilepsies, Partial</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lacosamide</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

